Coherus Q2 FY26 net loss narrows 25.67% to $33.3 million; revenue rises 39.51% to $14.3 millionPUBT·Aug 5 at 05:10 PMCHRS+5.26%
Coherus Oncology | 8-K: FY2026 Q2 Revenue Misses Estimate at USD 14.31 MEarnings Watch·Aug 5 at 04:33 PMCHRS+5.26%
Coherus Oncology to Report Second Quarter 2026 Financial Results on August 5, 2026 | CHRS Stock NewsStockTitan·Jul 22 at 04:36 AMCHRS+5.26%
Unbundling the Value Chain: Business Models from Digital Infrastructure to Physical ScaleGlobal Report·Jul 14 at 06:47 AMCHRS+5.26%REI+2.24%
Toyota's USD 3.6B Expansion and Oil Sector Buybacks Highlight Capital Shifts Beyond Big TechGlobal Report·Jul 9 at 05:03 AMJKS+2.82%TYOYY-3.34%
Coherus and Zumutor Biologics Announce Clinical Collaboration to Evaluate ZM008 in Combination with LOQTORZI® (toripalimab-tpzi) | CHRS Stock NewsStockTitan·Jun 23 at 05:00 AMCHRS+5.26%
Coherus Oncology shares are trading lower after the company reported mixed Q1 financial results.benzinga_article·May 12 at 10:51 AMCHRS+5.26%PBE-0.51%
